[Renaliste] adieu générateurs baxter

[jean claude glachant]

Baxter avait racheté Althin et sa ligne de générateurs,
en plein été 2005, Baxter laisse tomber les générateurs 
d'hémodialyse... pour se consacrer à la dialyse à domicile ! (sic)

Gambro va t'il abandonner la dialyse péritonéale ??


ci joint l'annonce officielle de baxter , extraite du site Baxter.com

On vit une époque épique...

jcg



Baxter Healthcare Corporation Announces Agreement to Distribute and 
Promote Gambro's Hemodialysis Instruments
 
-------------- section suivante --------------
Une pièce jointe non texte a été nettoyée...
Nom: non disponible
Type: text/enriched
Taille: 643 octets
Desc: non disponible
Url: http://rdplf.vps-hostingfr.com/mailman/private/renaliste/attachments/20050801/c4443689/attachment.bin
-------------- section suivante --------------
Une pièce jointe non texte a été nettoyée...
Nom: space.gif
Type: image/gif
Taille: 49 octets
Desc: non disponible
Url: http://rdplf.vps-hostingfr.com/mailman/private/renaliste/attachments/20050801/c4443689/space.gif
-------------- section suivante --------------
 
Baxter to Focus Internal Product Development Resources on Renal Home 
Therapy
 
DEERFIELD, Ill., July 21, 2005 ? Baxter Healthcare Corporation 
announced today it has entered into an agreement with Gambro Renal 
Products to distribute and promote Gambro's hemodialysis (HD) 
instruments worldwide. The company has concluded separately that it 
would discontinue the manufacture of HD instruments, however, current 
customers will continue to receive full support for the Baxter 
instruments in use in the field today. These decisions allow Baxter to 
continue to provide a complete and competitive in-center HD product 
offering, while further advancing its home therapy business, including 
peritoneal dialysis (PD), worldwide.
 
The agreement with Gambro is consistent with the company's strategy to 
optimize and improve the performance of its HD business while 
maintaining a broad portfolio of HD products for renal patients around 
the world. Baxter will now distribute Gambro's HD instruments and 
directly related ancillary products through the new distribution and 
promotion agreement. The company will continue to distribute its 
existing line of HD dialyzers, and provide HD solutions and 
concentrates that are manufactured by Baxter. This new approach enables 
Baxter to continue to focus internal product development resources on 
home therapies, drawing on its strengths in PD. Financial terms of the 
agreement were not disclosed.
 
?After considering our strategic alternatives, we are pleased to 
announce a distribution and promotion agreement with Gambro, a global 
leader in HD instrumentation,? said Bruce McGillivray, corporate vice 
president and president of Baxter's Renal business. ?This agreement 
will allow us to further build on our strong home therapy expertise, 
leveraging our global leadership position in PD, while we continue 
meeting the in-center needs of our customers.?
 
Baxter will have exclusive distribution rights for Gambro HD 
instruments throughout most of Latin America, and a non-exclusive 
distribution and promotion arrangement in the United States and the 
rest of the world, excluding Japan where Baxter does not participate in 
the HD market. In non-exclusive countries, Baxter and Gambro will each 
sell HD instruments and directly related ancillary products through 
their respective sales channels. Baxter will continue to provide 
customer service and spare parts support for its existing HD instrument 
base.
 
?We remain extremely committed to our customers and to the renal 
community,? McGillivray added. ?We will ensure that our current HD 
customers continue to receive support for the HD instruments that they 
have purchased from Baxter, while we make a seamless transition to 
Gambro's instruments.?
 
In connection with this agreement and the company's decision to 
discontinue hemodialysis instrument manufacturing, the company expects 
to record a charge in future quarters totaling $40 to $50 million.
 
Baxter Healthcare Corporation is a subsidiary of Baxter International 
Inc. (NYSE:BAX). Baxter International, through its subsidiaries, 
assists healthcare professionals and their patients with the treatment 
of complex medical conditions, including cancer, hemophilia, immune 
disorders, kidney disease and trauma. The company applies its expertise 
in medical devices, pharmaceuticals and biotechnology to make a 
meaningful difference in patients' lives.
 
This news release contains forward-looking statements within the 
meaning of the federal securities laws. These statements involve risks 
and uncertainties, including: the company's ability to realize in a 
timely manner the anticipated benefits of restructuring initiatives; 
the effect of economic conditions; the impact of geographic and/or 
product mix on the company's sales; actions of regulatory bodies and 
other governmental authorities, including the Food and Drug 
Administration and foreign counterparts that could delay, limit or 
suspend product sales and distribution; product quality and/or patient 
safety concerns leading to product recalls, withdrawals, launch delays 
or declining sales; product development risks; interest rates; 
technological advances in the medical field; demand for and market 
acceptance risks for new and existing products, and other technologies; 
the impact of competitive products and pricing, including generic 
competition, drug reimportation and disruptive technologies; inventory 
reductions or fluctuations in buying patterns by wholesalers or 
distributors; foreign currency exchange rates; the availability of 
acceptable raw materials and component supply; global regulatory, trade 
and tax policies; the ability to enforce patents; patents of third 
parties preventing or restricting the company's manufacture, sale or 
use of affected products or technology; reimbursement policies of 
government agencies and private payers; internal and external factors 
that could impact commercialization; results of product testing; and 
other risks detailed in the company's filings with the Securities and 
Exchange Commission. These forward-looking statements are based on 
estimates and assumptions within the bounds of management's knowledge 
of the company's business and operations, but there can be no assurance 
that the actual results or performance of the company will conform to 
any future results or performance expressed or implied by such 
forward-looking statements, and undue reliance should not be placed on 
them. Actual results could differ materially from such statements. 
Please refer to Baxter's Annual Report on Form 10-K, our Quarterly 
Reports on Form 10-Q and other documents filed by the company with the 
Securities and Exchange Commission, which are also available on 
Baxter's website, for more details concerning important factors that 
could cause actual results to differ materially. The company disclaims 
any current intention to update any forward-looking statements and all 
such statements speak only as of the time when made
-------------- section suivante --------------
Une pièce jointe non texte a été nettoyée...
Nom: non disponible
Type: text/enriched
Taille: 6204 octets
Desc: non disponible
Url: http://rdplf.vps-hostingfr.com/mailman/private/renaliste/attachments/20050801/c4443689/attachment-0001.bin